JP2018529081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529081A5 JP2018529081A5 JP2018502150A JP2018502150A JP2018529081A5 JP 2018529081 A5 JP2018529081 A5 JP 2018529081A5 JP 2018502150 A JP2018502150 A JP 2018502150A JP 2018502150 A JP2018502150 A JP 2018502150A JP 2018529081 A5 JP2018529081 A5 JP 2018529081A5
- Authority
- JP
- Japan
- Prior art keywords
- marker shown
- level
- levels
- sphingosine
- decreased
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003550 marker Substances 0.000 claims 64
- 230000003247 decreasing effect Effects 0.000 claims 23
- 230000001919 adrenal effect Effects 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 16
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 13
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 13
- 208000036546 leukodystrophy Diseases 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims 10
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 8
- 102000011690 Adiponectin Human genes 0.000 claims 8
- 108010076365 Adiponectin Proteins 0.000 claims 8
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 claims 8
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 4
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 4
- 230000007823 neuropathy Effects 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000000630 rising effect Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 101000779336 Oryza sativa subsp. japonica Fructose-bisphosphate aldolase 1, cytoplasmic Proteins 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 claims 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 229940121908 Retinoid X receptor agonist Drugs 0.000 claims 1
- 108010041191 Sirtuin 1 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382366.1A EP3118621A1 (en) | 2015-07-14 | 2015-07-14 | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| EP15382366.1 | 2015-07-14 | ||
| PCT/EP2016/066825 WO2017009437A1 (en) | 2015-07-14 | 2016-07-14 | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529081A JP2018529081A (ja) | 2018-10-04 |
| JP2018529081A5 true JP2018529081A5 (enExample) | 2019-07-11 |
Family
ID=53776537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502150A Pending JP2018529081A (ja) | 2015-07-14 | 2016-07-14 | 副腎白質ジストロフィーの診断ならびに治療のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190010535A1 (enExample) |
| EP (2) | EP3118621A1 (enExample) |
| JP (1) | JP2018529081A (enExample) |
| KR (1) | KR20180030074A (enExample) |
| CN (1) | CN107923897A (enExample) |
| AU (1) | AU2016293068A1 (enExample) |
| BR (1) | BR112018000749A2 (enExample) |
| CA (1) | CA2991586A1 (enExample) |
| CL (1) | CL2018000078A1 (enExample) |
| HK (1) | HK1253769A1 (enExample) |
| MX (1) | MX2018000464A (enExample) |
| WO (1) | WO2017009437A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US12172017B2 (en) * | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US11958805B2 (en) * | 2017-03-09 | 2024-04-16 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| US12276670B2 (en) | 2017-09-29 | 2025-04-15 | The General Hospital Corporation | Methods for identifying and treating adrenomyeloneuropathy (AMN) |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| KR102252167B1 (ko) * | 2018-11-22 | 2021-05-17 | 연세대학교 산학협력단 | X-연관 부신백질이영양증 진단용 바이오마커 조성물 |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| FR3132910A1 (fr) * | 2022-02-24 | 2023-08-25 | Universite De Bourgogne | Methodes pour le pronostic et le suivi des leucodystrophies peroxysomales |
| EP4431945A1 (en) * | 2023-03-16 | 2024-09-18 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Biomarkers discriminating the discordant phenotypes of x-adrenoleukodystrophy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1355193A (zh) * | 2000-12-01 | 2002-06-26 | 复旦大学 | 一种新的多肽——肾上腺脑白质营养不良相关蛋白10.78和编码这种多肽的多核苷酸 |
| CA2752003A1 (en) | 2009-02-24 | 2010-09-02 | Novartis Ag | Ceramide-analogous metabolites |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| ES2377381B1 (es) * | 2010-05-17 | 2013-03-14 | Fundació Institut De Investigació Biomèdica De Bellvitge (Idibell) | Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes. |
| JP2013533286A (ja) * | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
| WO2012112933A1 (en) * | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| AU2014205529B2 (en) * | 2013-01-08 | 2018-08-09 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
| JP2016519684A (ja) * | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
-
2015
- 2015-07-14 EP EP15382366.1A patent/EP3118621A1/en not_active Withdrawn
-
2016
- 2016-07-14 US US15/745,199 patent/US20190010535A1/en not_active Abandoned
- 2016-07-14 CN CN201680041132.6A patent/CN107923897A/zh active Pending
- 2016-07-14 JP JP2018502150A patent/JP2018529081A/ja active Pending
- 2016-07-14 BR BR112018000749A patent/BR112018000749A2/pt not_active IP Right Cessation
- 2016-07-14 AU AU2016293068A patent/AU2016293068A1/en not_active Abandoned
- 2016-07-14 WO PCT/EP2016/066825 patent/WO2017009437A1/en not_active Ceased
- 2016-07-14 MX MX2018000464A patent/MX2018000464A/es unknown
- 2016-07-14 EP EP16739131.7A patent/EP3322980B1/en active Active
- 2016-07-14 CA CA2991586A patent/CA2991586A1/en not_active Abandoned
- 2016-07-14 HK HK18107651.5A patent/HK1253769A1/zh unknown
- 2016-07-14 KR KR1020187003374A patent/KR20180030074A/ko not_active Withdrawn
-
2018
- 2018-01-10 CL CL2018000078A patent/CL2018000078A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529081A5 (enExample) | ||
| Ye et al. | Ferrostatin-1 mitigates cognitive impairment of epileptic rats by inhibiting P38 MAPK activation | |
| Souza et al. | Palmitoleic acid reduces the inflammation in LPS‐stimulated macrophages by inhibition of NF κB, independently of PPAR s | |
| JP5648216B2 (ja) | パーキンソン病治療医薬組成物 | |
| Joosten et al. | Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis | |
| Singh et al. | Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters | |
| Kurtys et al. | The combination of vitamins and omega-3 fatty acids has an enhanced anti-inflammatory effect on microglia | |
| Li et al. | Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP/PS1 mice by suppressing MAPK signaling | |
| SI3004106T1 (en) | Dual selective PI3 delta and gamma inhibitors | |
| MX2018004447A (es) | Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| MX2018001196A (es) | Compuesto derivado de amida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6 y composición farmacéutica que lo contiene. | |
| US11426366B2 (en) | Compositions and methods for treating motor disorders | |
| JP2015038155A5 (enExample) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| Chen et al. | Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy | |
| Ligsay et al. | Review of targeted treatments in fragile X syndrome | |
| JP2018537513A5 (enExample) | ||
| JP2016510340A5 (enExample) | ||
| RU2020107732A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| TWI870475B (zh) | 用於治療神經毒性之方法及材料 | |
| Seshadri et al. | Glucocorticoids inhibit group 3 innate lymphocyte IL-22 production | |
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| MY195058A (en) | Heterocyclicalkyl Derivative Compounds as Selective Histone Deacetylase Inhibitors and Pharmaceutical Compositions Comprising the Same |